# CollPlant Biotechnologies Ltd > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/CollPlant Biotechnologies Ltd). ## Overview CollPlant Biotechnologies Ltd. develops regenerative medicine products based on its recombinant human collagen technology platform. The company is focused on bioinks and scaffold materials used in 3D bioprinting, as well as tissue-related products for orthopedic, prosthetic, and surgical applications, with operations run from Israel and access to U.S. capital markets. ## Products & services • rhCollagen-based bioinks for 3D bioprinting • Ready-to-print BioInk formulations • Tissue scaffold materials • Regenerative medicine product development • Orthopedic and surgical biomaterials - **3D bioprinting bioinks** (45%) — Recombinant collagen-based inks used as the base material for bioprinting tissue constructs. - **Biomaterial scaffolds** (30%) — Collagen-derived scaffold materials designed to support tissue regeneration and implant applications. - **Regenerative medicine R&D** (15%) — Development programs that advance collagen-based platforms and related applications. - **Orthopedic and surgical materials** (10%) — Products and materials for orthopedic, prosthetic, and surgical uses. - rhCollagen-based bioinks for 3D bioprinting - Ready-to-print BioInk formulations - Tissue scaffold materials - Regenerative medicine product development - Orthopedic and surgical biomaterials ## Customers CollPlant sells into life sciences and regenerative medicine markets, where customers need advanced biomaterials for research, development, and clinical translation. Its buyers are typically biotechnology and medical-device partners, research organizations, and commercial collaborators that use collagen-based materials in bioprinting or tissue engineering workflows. End users are often hospitals, surgeons, and patients indirectly, through partner products or clinical programs. - **Biotechnology and medtech partners** (primary) — They buy collagen-based materials and platform access to develop regenerative and bioprinted products. - **Research institutions and labs** (secondary) — They use bioinks and scaffold materials for preclinical and translational research. - **Medical device and surgical customers** (secondary) — They incorporate biomaterials into orthopedic, prosthetic, or surgical applications. - Biotech and medtech partners developing regenerative products - Researchers using collagen bioinks for 3D printing - Medical device companies seeking biomaterial inputs - Clinical and surgical end markets reached through partners - Customers need reproducible, human-collagen-based materials ## Geography CollPlant is headquartered in Israel and serves a business model that is global in research, partnering, and commercialization. The company also accesses U.S. capital markets as a foreign private issuer, while its products and collaborations are relevant to customers across North America, Europe, and other international life-science markets. Geography matters because regulatory pathways, clinical adoption, and partner networks differ materially by region. - Headquartered in Rehovot, Israel - Operates as a foreign private issuer in the U.S. - Commercial and research markets are international - North America is important for capital and partnerships - Regulatory and clinical pathways vary by region ## Strategy CollPlant’s strategy centers on its recombinant human collagen platform and the expansion of its 3D bioprinting and regenerative medicine offerings. Recent disclosures point to product innovation around ready-to-print bioinks and continued development of its collagen-based portfolio, which supports differentiation with partners that need scalable, human-collagen materials. Protecting the platform’s technical position and advancing commercial collaborations are central to its long-term value creation. - **Expand rhCollagen product portfolio** (short-term) — A broader product set increases use cases and partner adoption in bioprinting and regenerative medicine. - **Build commercial collaborations** (medium-term) — Partners provide validation, distribution reach, and downstream commercialization pathways. - **Advance platform differentiation** (long-term) — Technical differentiation around recombinant human collagen supports pricing power and customer retention. - Expand the rhCollagen platform into new bioprinting products - Commercialize ready-to-print formulations for easier adoption - Advance partnerships in regenerative medicine and medtech - Differentiate through human-collagen biomaterials - Use platform innovation to widen application areas ## Risks CollPlant faces development, commercialization, and financing risks typical of early-stage biomaterials and medical technology companies. Its products depend on adoption by partners and customers, regulatory acceptance, and successful execution of product launches, while foreign issuer listing requirements and equity market conditions can also affect the business. Because revenue is tied to emerging applications, delays in partner programs or product adoption can have outsized effects. - **Commercialization and adoption risk** [high] — Bioinks and biomaterials must be adopted by partners and end users before they can scale meaningfully. - **Regulatory and clinical risk** [high] — Medical and tissue-related products require regulatory clearance and successful clinical or preclinical progress. - **Capital market and listing compliance risk** [medium] — The company depends on public-market access and must satisfy exchange requirements. - **Technology and execution risk** [high] — Platform companies must keep improving materials performance and manufacturing reproducibility. - Product adoption depends on partner and customer validation - Regulatory and clinical timelines can delay commercialization - Emerging market demand may be uneven and hard to forecast - Nasdaq listing compliance can affect market access - Development-stage businesses face funding and dilution risk ## Accounting As a development-stage biotech and biomaterials company, CollPlant’s reported results are sensitive to judgments around research spending, share-based compensation, and any capitalization of development-related costs. Lease accounting and foreign-currency translation can also affect reported expenses and balance sheet items because the business operates from Israel but reports in U.S. dollars. Investors should also watch for impairment or valuation issues if intangible assets, equipment, or strategic investments are recorded. - **Research and development expense** — Material to operating results - **Share-based compensation** — Affects operating loss and EPS - **Foreign currency translation** — Affects cash, expenses, and equity - **Lease accounting** — Affects leverage and asset base - Research and development spend drives period expense - Share-based compensation affects operating results - Lease accounting influences reported assets and liabilities - FX translation matters for Israel-based operations - Impairment and valuation judgments may affect asset values --- *Last updated: 2026-09-28T11:58:14.579000+00:00*